Blackstone Life Sciences is placing a bet on Pfizer’s berobenatide, a GLP-1 drug designed for monthly dosing. This GLP-1 drug comes from Metsera, which Pfizer acquired last year in a $10 billion deal.
The post Pfizer Deal With Blackstone Secures Up to $1.5B to Bankroll GLP-1 Drug Trials appeared first on MedCity News.
